Cost-Utility Analysis of Cannabidiol for Seizures in Patients with Lennox-Gastaut or Dravet Syndrome
Author Information
Author(s): Siddiqui Jamshaed, Bowditch Sally
Primary Institution: FIECON, London, UK
Hypothesis
Is cannabidiol plus usual care more cost-effective than usual care alone for treating seizures in patients with Lennox-Gastaut syndrome or Dravet syndrome in the Netherlands?
Conclusion
Cannabidiol plus usual care is cost-effective compared to usual care alone for patients with treatment-resistant Lennox-Gastaut syndrome or Dravet syndrome in the Netherlands.
Supporting Evidence
- CBD plus usual care led to additional costs of €28,338 and increased QALYs of 1.318 compared to usual care alone in patients with LGS.
- In patients with DS, CBD plus usual care dominated usual care alone, with cost savings of €23,642 and increased QALYs of 0.868.
- The probability that CBD plus usual care is cost-effective is 96% for LGS and 99% for DS.
Takeaway
This study found that adding cannabidiol to usual care helps kids with severe epilepsy have fewer seizures and is worth the extra cost.
Methodology
A cohort-based Markov model was developed to analyze costs and outcomes from a societal perspective over a lifetime horizon.
Potential Biases
Data collection relied on expert opinions and vignette-based methods, which may introduce bias.
Limitations
Long-term clinical data for CBD are lacking, and assumptions were made regarding the durability of treatment effects.
Participant Demographics
Patients aged 2 years or older with treatment-resistant Lennox-Gastaut syndrome or Dravet syndrome.
Statistical Information
P-Value
21,493
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website